JP2003532618A5 - - Google Patents

Download PDF

Info

Publication number
JP2003532618A5
JP2003532618A5 JP2000549639A JP2000549639A JP2003532618A5 JP 2003532618 A5 JP2003532618 A5 JP 2003532618A5 JP 2000549639 A JP2000549639 A JP 2000549639A JP 2000549639 A JP2000549639 A JP 2000549639A JP 2003532618 A5 JP2003532618 A5 JP 2003532618A5
Authority
JP
Japan
Prior art keywords
disease
use according
antigen
neuropathy
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000549639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003532618A (ja
Filing date
Publication date
Priority claimed from IL12455098A external-priority patent/IL124550A0/xx
Priority claimed from PCT/US1998/014715 external-priority patent/WO1999034827A1/en
Priority claimed from US09/218,277 external-priority patent/US20030108528A1/en
Application filed filed Critical
Priority claimed from PCT/US1999/010953 external-priority patent/WO1999060021A2/en
Publication of JP2003532618A publication Critical patent/JP2003532618A/ja
Publication of JP2003532618A5 publication Critical patent/JP2003532618A5/ja
Abandoned legal-status Critical Current

Links

JP2000549639A 1998-05-19 1999-05-19 細胞、神経系−特異的抗原およびそれらの用途 Abandoned JP2003532618A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IL12455098A IL124550A0 (en) 1997-07-21 1998-05-19 Compositions comprising activated t-cells or t-cell activating agents and their use
IL124550 1998-05-19
US9814715 1998-07-21
PCT/US1998/014715 WO1999034827A1 (en) 1998-07-21 1998-07-21 Activated t-cells and their uses
US09/218,277 US20030108528A1 (en) 1998-05-19 1998-12-22 Activated t-cells, nervous system-specific antigens and their uses
US09/218,277 1998-12-22
PCT/US1999/010953 WO1999060021A2 (en) 1998-05-19 1999-05-19 Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system

Publications (2)

Publication Number Publication Date
JP2003532618A JP2003532618A (ja) 2003-11-05
JP2003532618A5 true JP2003532618A5 (https=) 2006-08-03

Family

ID=27271868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000549639A Abandoned JP2003532618A (ja) 1998-05-19 1999-05-19 細胞、神経系−特異的抗原およびそれらの用途

Country Status (4)

Country Link
EP (1) EP1080110A2 (https=)
JP (1) JP2003532618A (https=)
CA (1) CA2328612A1 (https=)
WO (1) WO1999060021A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
IL160105A0 (en) 2001-12-06 2004-06-20 Yeda Res & Dev Vaccine for treatment of motor neurone diseases
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2892353A4 (en) 2012-09-10 2016-10-26 Yeda Res & Dev INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001746A1 (en) * 1989-08-09 1991-02-21 The Children's Medical Center Corporation Thy-1 receptor and its use for regenerating nerve cell processes
DE69320967T2 (de) * 1992-04-09 1999-05-12 Autoimmune, Inc., Lexington, Mass. Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
CZ122697A3 (en) * 1994-10-25 1997-09-17 Immulogic Pharma Corp Preparations and methods of treating disseminated sclerosis
ATE275415T1 (de) * 1995-06-27 2004-09-15 Res Foundation Of Cuny Hunter Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
US5800812A (en) * 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
SE505316C2 (sv) * 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
AU5671196A (en) * 1996-03-28 1997-10-17 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
AU3134799A (en) * 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration

Similar Documents

Publication Publication Date Title
JP2003532618A5 (https=)
Schrempf et al. Glatiramer acetate: mechanisms of action in multiple sclerosis
Subklewe et al. Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study
JP2004507460A5 (https=)
EP1126874B2 (en) Multicomponent meningococcal vaccine
RU2387453C2 (ru) Композиции и способы лечения неврологических нарушений
WO2006121656A3 (en) Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
JP2004500354A (ja) 全ｄ体ペプチドを含む、アルツハイマー病およびアミロイド関連疾患の予防および処置のためのワクチン
JP2017042172A5 (https=)
US20230218730A1 (en) Vaccine therapy for ran protein diseases
JOP20210284A1 (ar) الإعطاء غير المتجانس للقاحات تاو
CN102580069B (zh) 用于治疗性免疫接种的含共聚物1的滴眼用疫苗
WO2012056344A1 (es) Uso de una composición en base a espironolactona, que presenta una acción inhibitoria de la activación de linfocitos t útil para prevenir y/o tratar esclerosis múltiple
JPWO2020092107A5 (https=)
Palumbo et al. Immunomodulation induced by central nervous system‐related peptides as a therapeutic strategy for neurodegenerative disorders
Liblau Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role
US20150147388A1 (en) Materials and Methods for Modulating immune Responses
KR20240147981A (ko) 항-알파시누클레인 치료 백신
US9770496B2 (en) Method for treating amyloid disease
KR102810481B1 (ko) 다발성경화증 치료용 백신
WO2026080609A1 (en) Compositions and methods for degradation-enhanced immunotherapies
TW202011949A (zh) 苯甲酸或其鹽及衍生物用於預防或治療抗ｎ－甲基－ｄ－天冬胺酸受體腦炎之用途
Arneth Protective autoimmunity and protein localization
Pier Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
CN118660717A (zh) 抗α-突触核蛋白的治疗性疫苗